Adjuvant High Dose Erythropoietin with Delayed Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy

Piyathida Jongruk,Nawamon Soontaravarapas,Salita Angkurawaranon,Shanika Kosarat,Varangthip Khuwuthyakorn,Watcharee Tantiprabha,Satit Manopunya,Nonglak Boonchooduang,Orawan Louthrenoo,Narueporn Likhitweerawong,Kamornwan Katanyuwong,Chinnuwat Sanguansermsri,Natrujee Wiwattanadittakul
DOI: https://doi.org/10.1016/j.pediatrneurol.2024.10.003
IF: 4.21
2024-10-11
Pediatric Neurology
Abstract:Background Therapeutic hypothermia (TH) is the standard of treatment for moderate to severe HIE. However, half of asphyxiated babies have a disability despite undergoing hypothermia. Erythropoietin (EPO) is a potential neuroprotective agent. Objective To evaluate the benefits of high-dose EPO combined with TH on brain magnetic resonance imaging (MRI) scores and neurodevelopmental outcomes in neonates with moderate-to-severe HIE, especially in neonates who received TH between 6–12 h of birth. Methods This prospective, single-blinded, randomized, placebo-controlled trial enrolled term newborns with moderate to severe HIE admitted to neonatal ICU between April 2018 and April 2022. Hypothermia was started within 12 hours of age. Infants were randomized to receive EPO 1000 units/kg or an equal volume of normal saline (placebo) on days 1,2,3,5 and 7 of age in combination with hypothermia. Results Fifty-seven neonates with moderate-to-severe HIE were recruited; ten were excluded. Forty-seven patients were included: 32 received TH within 6 hours (group I) and 15 TH was started within 6–12 h of birth (group II). The clinical characteristics of mothers, infants, maternal complications, and resuscitations performed during the perinatal period showed no statistical differences between EPO and placebo groups I and II. The MRI scores and brain injury patterns did not differ between the EPO and placebo groups. There is no statistical significance in either group's seizure and severe EEG background (initial and after rewarming) between EPO and placebo in each group. There were no differences in developmental outcomes (Abnormal Denver II >2 area, GMFCS >1), BSID-III score (cognitive, language, and motor), or disability (hearing impairment and impaired vision) between the EPO and placebo Groups I and II at 12 and 18 months. Conclusions Among term infants with moderate-to-severe HIE, TH with EPO administration, compared with TH alone, did not reduce brain injury on MRI or reduce the risk of neurological sequelae both in TH within 6 h and in patients who received TH late later (6–12 h). Further studies on the benefit of EPO injection alone or before TH in situations where TH cannot be performed are required.
pediatrics,clinical neurology
What problem does this paper attempt to address?